NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) — Integral Acquisition Corporation 1 (the “Company”) announced today that due to its inability to complete an initial business combination within the time period required by its fifth amended and restated certificate of incorporation, the Company intends to liquidate and dissolve, effective as of the close of business on November 5, 2026, and will redeem all of the outstanding shares of its Class A common stock that were included in the units issued to public stockholders in its initial public offering (the “Public Shares”), at a per-share redemption price equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to the Company to pay its taxes payable and up to $100,000 of interest to pay dissolution expenses, divided by the number of outstanding Public Shares.

In order to provide for the disbursement of funds from the Company’s trust account on November 27, 2026, the Company has instructed Continental Stock Transfer & Trust Company (“Continental”), as its trustee, to take all necessary actions to liquidate the securities held in the trust account. Of the $100,000 of interest permitted to be withdrawn for taxes and dissolution expenses, $57,891.80 in interest is available for withdrawal and will be withdrawn to pay a portion of such expenses. The remaining proceeds will be held in a trust operating account while awaiting disbursement to the holders of the Public Shares, at a per share price of approximately $11.61 (the “Redemption Amount”). All other costs and expenses associated with implementing the Company’s plan of dissolution will be funded from proceeds held outside of the trust account. Record holders will receive their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental, the Company’s transfer agent. Beneficial owners of Public Shares held in “street name,” however, will not need to take any action in order to receive the Redemption Amount. The Redemption Amount is expected to be paid out on or about November 27, 2026.

The Company’s sponsor has agreed to waive its redemption rights with respect to its founder shares issued in a private placement in connection with the Company’s initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless. The Company’s securities are expected to cease trading on November 27, 2026.

About Integral Acquisition Corporation 1

Integral Acquisition Corporation 1 is a blank check company, also commonly referred to as a special purpose acquisition company, formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. For more information, please visit https://www.integralacquisition.com.

 Forward-Looking Statements

This press release may include, and oral statements made from time to time by representatives of the Company may include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding the Company’s liquidation and the redemptions thereto, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (the “SEC”). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact 
Integral Acquisition Corporation 1
info@integralacquisition.com

The microgrid AZIO AI will build as general contractor is designed to keep the base running for up to 14 days without the commercial grid, using the same on-site approach the company applies behind its AI campuses

HOUSTON, Nov. 20, 2026 (GLOBE NEWSWIRE) — When the commercial grid goes down, an Army installation still has a mission to carry out. At Fort Buchanan, Puerto Rico, a microgrid now under contract is designed to let the base keep running on its own power for up to 14 days.

AZIO AI Holdings, Inc. (Nasdaq: AZIO) is general contractor on the approximately $45.0 million Fort Buchanan microgrid. The project is part of about $144.6 million in awarded U.S. Army microgrid work held by prime contractor Energy Resilience Partners, LLC (“ERP”). Here is what it means for the base and for Puerto Rico’s next generation of power and digital infrastructure.

WHAT THE BASE GETS

The Army awarded the Fort Buchanan contract (W912QR26CA025) to ERP on Aug. 20, 2026. The work adds four continuous-duty 2 MW diesel generators and a 5 MWh battery energy storage system, tied into an existing 4.65 MW solar array and two 275 kW wind turbines.

The base gets four kinds of power working as one system: solar and wind supply energy when they can, the battery stores it, the generators carry the load when needed, and controls tie it together. If the commercial grid fails, the microgrid is designed to keep the installation running for up to 14 days without it.

MISSION ASSURANCE

An installation does not get to pause its mission while the lights are out. The point of the project is energy resilience that is on site and does not depend on anything outside the fence.

OFF-GRID, BY DESIGN

AZIO’s Project Atlas is its program for behind-the-meter AI campuses in Texas. The idea is to make the power on site and not wait on a utility; Atlas One is designed to run fully off the ERCOT grid. A base that can run without the commercial grid needs the same things: on-site generation, storage and controls. The customer and the load are different. The work is the same.

A PATTERN FOR THE NEXT GENERATION

Puerto Rico’s next generation of infrastructure, whether it keeps an Army base running or powers digital services, will depend on electricity that stays on. Fort Buchanan’s design points to one way to get there: use the sun and wind already on site, store that energy, back it with dependable generation, and manage it all with controls.

That is the engineering AZIO applies to AI compute. Power-hungry digital infrastructure and mission-critical military infrastructure share one requirement: power that does not depend on everything outside the site going right. AZIO expects the experience of delivering resilient power for the Army to inform its other power and infrastructure work, including Atlas.

Neither AZIO nor ERP has AI or data-center work on any military installation.

THE ARMY CONTEXT

The Army has set a goal of a microgrid on every installation by 2035. On Sept. 30, 2026, Secretary of War Pete Hegseth announced FORTRESS America, a future Department of War program calling for every U.S. military installation to eventually run under its own power. ERP’s contracts were awarded before FORTRESS America was announced and are not FORTRESS America awards.

PROFIT PARTICIPATION

Under a profit-participation agreement with ERP, AZIO has a contractual right to 41.5% of ERP’s net profit, as defined in that agreement, from the projects it covers. No margin is guaranteed, and AZIO is not providing revenue or profit projections.

HOW THE WORK IS STRUCTURED

AZIO is paid as it performs: its costs plus a fee as general contractor at Fort Buchanan. The $144.6 million is the value of ERP’s two prime contracts with the U.S. Army, including options. It is not AZIO’s revenue. Work on both contracts starts only when ERP delivers, and the U.S. Army accepts, ERP’s performance and payment bonds. Each project is expected to take about three years once work begins.

IN HIS WORDS

“The next generation of infrastructure, whether it’s an Army base or an AI campus, starts with power that keeps running when the grid doesn’t. At Fort Buchanan we’re putting solar, wind, storage and generation to work as one system so the base can keep going on its own. Same business, different mission.” — Elgin Tracy, Chief Operating Officer of AZIO AI

Larry G. Paige II, a director of AZIO, serves as Executive Director of ERP.

AZIO AI Holdings, Inc. (Nasdaq: AZIO) develops AI compute and power infrastructure. Project Atlas is its program for behind-the-meter, power-backed AI compute campuses in Texas. More information: www.azioai.ai.

CONTACT

PR & Global Media:

Phoenix MGMT & Consulting

PR@PhoenixMGMTConsulting.com

888-228-0122

AZIO AI Holdings, Inc. · 7510 Ardmore Street, Houston, TX 77054 · www.azioai.ai

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about the delivery and acceptance of ERP’s performance and payment bonds; the start, duration, scope and completion of the Fort Buchanan project; the exercise of contract options; AZIO’s compensation as general contractor; AZIO’s profit participation under its agreement with ERP; the expected capabilities of the microgrid, including its design to keep the installation running for up to 14 days without the commercial grid; the expected benefits of the project to the base, to Puerto Rico and to AZIO’s AI infrastructure business; and the Atlas program. Actual results may differ materially because of, among other things, delays in or failure to deliver ERP’s performance and payment bonds; ERP’s performance of its obligations under each government contract; the risk that contract options are not exercised; the terms, approval and enforceability of AZIO’s profit-participation agreement with ERP, including whether any project generates net profit; congressional funding and appropriations; contract modification, audit, delay, suspension or termination for convenience; AZIO’s dependence on ERP as prime contractor and on subcontractors, suppliers and equipment vendors; AZIO’s limited operating history in federal construction and energy infrastructure; cost increases, supply chain, labor, weather (including hurricanes in Puerto Rico) and site risks; and the risks described in AZIO’s most recent Form 10-K and subsequent Form 10-Q filings at www.sec.gov. AZIO undertakes no obligation to update these statements except as required by law. This press release is not an offer to sell or a solicitation of an offer to buy any security.

The microgrid AZIO AI will build as general contractor is designed to keep the base running for up to 14 days without the commercial grid, using the same on-site approach the company applies behind its AI campuses

HOUSTON, Nov. 20, 2026 (GLOBE NEWSWIRE) — When the commercial grid goes down, an Army installation still has a mission to carry out. At Fort Buchanan, Puerto Rico, a microgrid now under contract is designed to let the base keep running on its own power for up to 14 days.

AZIO AI Holdings, Inc. (Nasdaq: AZIO) is general contractor on the approximately $45.0 million Fort Buchanan microgrid. The project is part of about $144.6 million in awarded U.S. Army microgrid work held by prime contractor Energy Resilience Partners, LLC (“ERP”). Here is what it means for the base and for Puerto Rico’s next generation of power and digital infrastructure.

WHAT THE BASE GETS

The Army awarded the Fort Buchanan contract (W912QR26CA025) to ERP on Aug. 20, 2026. The work adds four continuous-duty 2 MW diesel generators and a 5 MWh battery energy storage system, tied into an existing 4.65 MW solar array and two 275 kW wind turbines.

The base gets four kinds of power working as one system: solar and wind supply energy when they can, the battery stores it, the generators carry the load when needed, and controls tie it together. If the commercial grid fails, the microgrid is designed to keep the installation running for up to 14 days without it.

MISSION ASSURANCE

An installation does not get to pause its mission while the lights are out. The point of the project is energy resilience that is on site and does not depend on anything outside the fence.

OFF-GRID, BY DESIGN

AZIO’s Project Atlas is its program for behind-the-meter AI campuses in Texas. The idea is to make the power on site and not wait on a utility; Atlas One is designed to run fully off the ERCOT grid. A base that can run without the commercial grid needs the same things: on-site generation, storage and controls. The customer and the load are different. The work is the same.

A PATTERN FOR THE NEXT GENERATION

Puerto Rico’s next generation of infrastructure, whether it keeps an Army base running or powers digital services, will depend on electricity that stays on. Fort Buchanan’s design points to one way to get there: use the sun and wind already on site, store that energy, back it with dependable generation, and manage it all with controls.

That is the engineering AZIO applies to AI compute. Power-hungry digital infrastructure and mission-critical military infrastructure share one requirement: power that does not depend on everything outside the site going right. AZIO expects the experience of delivering resilient power for the Army to inform its other power and infrastructure work, including Atlas.

Neither AZIO nor ERP has AI or data-center work on any military installation.

THE ARMY CONTEXT

The Army has set a goal of a microgrid on every installation by 2035. On Sept. 30, 2026, Secretary of War Pete Hegseth announced FORTRESS America, a future Department of War program calling for every U.S. military installation to eventually run under its own power. ERP’s contracts were awarded before FORTRESS America was announced and are not FORTRESS America awards.

PROFIT PARTICIPATION

Under a profit-participation agreement with ERP, AZIO has a contractual right to 41.5% of ERP’s net profit, as defined in that agreement, from the projects it covers. No margin is guaranteed, and AZIO is not providing revenue or profit projections.

HOW THE WORK IS STRUCTURED

AZIO is paid as it performs: its costs plus a fee as general contractor at Fort Buchanan. The $144.6 million is the value of ERP’s two prime contracts with the U.S. Army, including options. It is not AZIO’s revenue. Work on both contracts starts only when ERP delivers, and the U.S. Army accepts, ERP’s performance and payment bonds. Each project is expected to take about three years once work begins.

IN HIS WORDS

“The next generation of infrastructure, whether it’s an Army base or an AI campus, starts with power that keeps running when the grid doesn’t. At Fort Buchanan we’re putting solar, wind, storage and generation to work as one system so the base can keep going on its own. Same business, different mission.” — Elgin Tracy, Chief Operating Officer of AZIO AI

Larry G. Paige II, a director of AZIO, serves as Executive Director of ERP.

AZIO AI Holdings, Inc. (Nasdaq: AZIO) develops AI compute and power infrastructure. Project Atlas is its program for behind-the-meter, power-backed AI compute campuses in Texas. More information: www.azioai.ai.

CONTACT

PR & Global Media:

Phoenix MGMT & Consulting

PR@PhoenixMGMTConsulting.com

888-228-0122

AZIO AI Holdings, Inc. · 7510 Ardmore Street, Houston, TX 77054 · www.azioai.ai

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about the delivery and acceptance of ERP’s performance and payment bonds; the start, duration, scope and completion of the Fort Buchanan project; the exercise of contract options; AZIO’s compensation as general contractor; AZIO’s profit participation under its agreement with ERP; the expected capabilities of the microgrid, including its design to keep the installation running for up to 14 days without the commercial grid; the expected benefits of the project to the base, to Puerto Rico and to AZIO’s AI infrastructure business; and the Atlas program. Actual results may differ materially because of, among other things, delays in or failure to deliver ERP’s performance and payment bonds; ERP’s performance of its obligations under each government contract; the risk that contract options are not exercised; the terms, approval and enforceability of AZIO’s profit-participation agreement with ERP, including whether any project generates net profit; congressional funding and appropriations; contract modification, audit, delay, suspension or termination for convenience; AZIO’s dependence on ERP as prime contractor and on subcontractors, suppliers and equipment vendors; AZIO’s limited operating history in federal construction and energy infrastructure; cost increases, supply chain, labor, weather (including hurricanes in Puerto Rico) and site risks; and the risks described in AZIO’s most recent Form 10-K and subsequent Form 10-Q filings at www.sec.gov. AZIO undertakes no obligation to update these statements except as required by law. This press release is not an offer to sell or a solicitation of an offer to buy any security.

The microgrid AZIO AI will build as general contractor is designed to keep the base running for up to 14 days without the commercial grid, using the same on-site approach the company applies behind its AI campuses

HOUSTON, Nov. 20, 2026 (GLOBE NEWSWIRE) — When the commercial grid goes down, an Army installation still has a mission to carry out. At Fort Buchanan, Puerto Rico, a microgrid now under contract is designed to let the base keep running on its own power for up to 14 days.

AZIO AI Holdings, Inc. (Nasdaq: AZIO) is general contractor on the approximately $45.0 million Fort Buchanan microgrid. The project is part of about $144.6 million in awarded U.S. Army microgrid work held by prime contractor Energy Resilience Partners, LLC (“ERP”). Here is what it means for the base and for Puerto Rico’s next generation of power and digital infrastructure.

WHAT THE BASE GETS

The Army awarded the Fort Buchanan contract (W912QR26CA025) to ERP on Aug. 20, 2026. The work adds four continuous-duty 2 MW diesel generators and a 5 MWh battery energy storage system, tied into an existing 4.65 MW solar array and two 275 kW wind turbines.

The base gets four kinds of power working as one system: solar and wind supply energy when they can, the battery stores it, the generators carry the load when needed, and controls tie it together. If the commercial grid fails, the microgrid is designed to keep the installation running for up to 14 days without it.

MISSION ASSURANCE

An installation does not get to pause its mission while the lights are out. The point of the project is energy resilience that is on site and does not depend on anything outside the fence.

OFF-GRID, BY DESIGN

AZIO’s Project Atlas is its program for behind-the-meter AI campuses in Texas. The idea is to make the power on site and not wait on a utility; Atlas One is designed to run fully off the ERCOT grid. A base that can run without the commercial grid needs the same things: on-site generation, storage and controls. The customer and the load are different. The work is the same.

A PATTERN FOR THE NEXT GENERATION

Puerto Rico’s next generation of infrastructure, whether it keeps an Army base running or powers digital services, will depend on electricity that stays on. Fort Buchanan’s design points to one way to get there: use the sun and wind already on site, store that energy, back it with dependable generation, and manage it all with controls.

That is the engineering AZIO applies to AI compute. Power-hungry digital infrastructure and mission-critical military infrastructure share one requirement: power that does not depend on everything outside the site going right. AZIO expects the experience of delivering resilient power for the Army to inform its other power and infrastructure work, including Atlas.

Neither AZIO nor ERP has AI or data-center work on any military installation.

THE ARMY CONTEXT

The Army has set a goal of a microgrid on every installation by 2035. On Sept. 30, 2026, Secretary of War Pete Hegseth announced FORTRESS America, a future Department of War program calling for every U.S. military installation to eventually run under its own power. ERP’s contracts were awarded before FORTRESS America was announced and are not FORTRESS America awards.

PROFIT PARTICIPATION

Under a profit-participation agreement with ERP, AZIO has a contractual right to 41.5% of ERP’s net profit, as defined in that agreement, from the projects it covers. No margin is guaranteed, and AZIO is not providing revenue or profit projections.

HOW THE WORK IS STRUCTURED

AZIO is paid as it performs: its costs plus a fee as general contractor at Fort Buchanan. The $144.6 million is the value of ERP’s two prime contracts with the U.S. Army, including options. It is not AZIO’s revenue. Work on both contracts starts only when ERP delivers, and the U.S. Army accepts, ERP’s performance and payment bonds. Each project is expected to take about three years once work begins.

IN HIS WORDS

“The next generation of infrastructure, whether it’s an Army base or an AI campus, starts with power that keeps running when the grid doesn’t. At Fort Buchanan we’re putting solar, wind, storage and generation to work as one system so the base can keep going on its own. Same business, different mission.” — Elgin Tracy, Chief Operating Officer of AZIO AI

Larry G. Paige II, a director of AZIO, serves as Executive Director of ERP.

AZIO AI Holdings, Inc. (Nasdaq: AZIO) develops AI compute and power infrastructure. Project Atlas is its program for behind-the-meter, power-backed AI compute campuses in Texas. More information: www.azioai.ai.

CONTACT

PR & Global Media:

Phoenix MGMT & Consulting

PR@PhoenixMGMTConsulting.com

888-228-0122

AZIO AI Holdings, Inc. · 7510 Ardmore Street, Houston, TX 77054 · www.azioai.ai

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about the delivery and acceptance of ERP’s performance and payment bonds; the start, duration, scope and completion of the Fort Buchanan project; the exercise of contract options; AZIO’s compensation as general contractor; AZIO’s profit participation under its agreement with ERP; the expected capabilities of the microgrid, including its design to keep the installation running for up to 14 days without the commercial grid; the expected benefits of the project to the base, to Puerto Rico and to AZIO’s AI infrastructure business; and the Atlas program. Actual results may differ materially because of, among other things, delays in or failure to deliver ERP’s performance and payment bonds; ERP’s performance of its obligations under each government contract; the risk that contract options are not exercised; the terms, approval and enforceability of AZIO’s profit-participation agreement with ERP, including whether any project generates net profit; congressional funding and appropriations; contract modification, audit, delay, suspension or termination for convenience; AZIO’s dependence on ERP as prime contractor and on subcontractors, suppliers and equipment vendors; AZIO’s limited operating history in federal construction and energy infrastructure; cost increases, supply chain, labor, weather (including hurricanes in Puerto Rico) and site risks; and the risks described in AZIO’s most recent Form 10-K and subsequent Form 10-Q filings at www.sec.gov. AZIO undertakes no obligation to update these statements except as required by law. This press release is not an offer to sell or a solicitation of an offer to buy any security.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

FOR IMMEDIATE RELEASE

20 November 2026

RECOMMENDED CASH OFFER

FOR

IRISH CONTINENTAL GROUP, PLC

BY

BLUEFIN BIDCO LIMITED

TO BE IMPLEMENTED BY WAY OF A SCHEME OF ARRANGEMENT UNDER CHAPTER 1 OF PART 9 OF THE COMPANIES ACT 2014 

SCHEME EFFECTIVE AND COMPLETION OF THE ACQUISITION

The Independent Directors of Irish Continental Group, plc (“ICG”) are pleased to announce that the scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 (the “Scheme”) in connection with the final recommended cash offer by Bluefin Bidco Limited (“BidCo”), for the entire issued and to be issued share capital of ICG (other than the Excluded Shares) (the “Acquisition”), became effective today 20 November 2026 (the “Effective Date”).

In accordance with the requirements of the Irish Takeover Rules, all consideration paid by BidCo to Scheme Shareholders under the terms of the Scheme will be distributed by no later than 4 December 2026.

Cancellation of the admission of ICG Units to trading on the regulated market of Euronext Dublin and the listing of ICG Units on the Official List of Euronext Dublin is expected to occur at 7.00 a.m. on 23 November 2026 (being the first business day following the Effective Date). Cancellation of the admission of ICG Units to trading on the Main Market of the London Stock Exchange and the FCA’s Official List is expected to occur at 8.00 a.m on 23 November 2026 (being the first business day following the Effective Date).

Capitalised terms used, but not defined, in this Announcement have the same meaning as in the Scheme Document dated 5 August 2026. All times stated in this Announcement are to time in Dublin.   

Enquiries

Irish Continental Group, plc
Brian Holland

+353 1 607 5700
investor.relations@icg.ie
PJT Partners (UK) Limited (Financial Adviser and Rule 3 Adviser to ICG)
Basil Geoghegan
Ronan Crotty
Henry Lebus

+44 (0)20 3650 1100
Q4 Public Relations (Public Relations Adviser to ICG)
Gerry O’Sullivan
+353 87 259 7644
gerry@q4pr.ie
   

Responsibility Statement

The Independent ICG Board accept responsibility for the information contained in this Announcement, To the best of the knowledge and belief of the Independent ICG Board (which has taken all reasonable care to ensure such is the case), the information contained in this Announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information. 

Adviser

PJT Partners, which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, is acting exclusively as financial adviser to ICG and no one else in connection with the matters described herein and will not be responsible to anyone other than ICG for providing the protections afforded to clients of PJT Partners nor for providing advice in connection with the matters described herein. Neither PJT Partners nor any of its subsidiaries, branches or affiliates nor any of their respective directors, officers, employees, agents or representatives owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of PJT Partners in connection with this Announcement, the Acquisition, any statement contained herein or otherwise.

No Offer or Solicitation

This Announcement is for information purposes only and is not intended to, and does not, constitute or form any part of any offer or invitation, or the solicitation of an offer, to purchase or otherwise acquire, subscribe for, sell or otherwise dispose of any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

PARSIPPANY, N.J., Nov. 20, 2026 (GLOBE NEWSWIRE) — Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal fourth quarter and full year 2026 financial results, provide an operational update, including preliminary fiscal year 2027 financial guidance, and host a question and answer session at 8:00 a.m. Eastern Time (ET) on Tuesday, November 24, 2026.

Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.embecta.com.

A webcast replay of the call will be available beginning at 11:00 a.m. ET on November 24, 2026, via the embecta investor relations website and archived on the website for one year.

About embecta
embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,500 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.

Contacts:   
   
Media  Investors 
Christian Glazar  Patricia Gonzalez
Sr. Director, Corporate Communications  VP, Corporate FP&A and Investor Relations
908-821-6922  862-341-2809
Contact Media Relations  Contact IR

X-CUE Smart Glasses Ready for Clinical Trials Following Over a Decade of Development

X-CUE Smart

WILMINGTON, Del., Nov. 20, 2026 (GLOBE NEWSWIRE) — Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that on November 19, 2026, it entered into a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. (“NeuroQ”) and Laonz Co., Ltd. (“Laonz”) to expand its business into medical device technologies designed to assist patients with Parkinson’s disease.

The agreement focuses on X-CUE, an augmented-reality smart-glasses technology developed over more than a decade to assist patients with Parkinson’s disease who experience freezing of gait, a condition that can significantly affect mobility and daily activities.

X-CUE augmented-reality smart-glasses technology (product illustration).

X-CUE augmented-reality smart-glasses technology (product illustration).

X-CUE uses augmented-reality visual cues designed to help patients manage freezing-of-gait episodes and support mobility. According to the technology developers, X-CUE has completed its product development phase for the latest, third-revised version of its medical device and is ready for planned clinical trials intended to support commercialization, with an anticipated clinical evaluation period of approximately six months.

Strategic Investment and Business Expansion
Under the agreement, Exicure intends to acquire an equity interest ranging from 20% to 100% in NeuroQ, primarily through the issuance of Exicure common shares in exchange for NeuroQ shares held by Laonz.

The final acquisition percentage, share exchange ratio, and other transaction terms will be determined through subsequent written agreements, subject to applicable corporate and regulatory approvals and Nasdaq requirements.

Following completion of the proposed share acquisition, Exicure intends to provide up to US$500,000 in development funding to support X-CUE’s clinical evaluation, regulatory advancement, manufacturing preparation, and commercialization initiatives, subject to applicable approvals, funding availability, and definitive funding arrangements.

Advancing X-CUE Toward Commercialization
Laonz has completed the transfer of the X-CUE business, including related intellectual property, technology, assets, and business rights, to NeuroQ.

NeuroQ will lead the continued development, clinical evaluation, regulatory approval, and commercialization of X-CUE, with strategic support from Exicure.

The parties intend to leverage the technology’s extensive development history and current product readiness to advance X-CUE through the remaining clinical and regulatory processes toward potential commercialization.

“Through this strategic agreement, we are expanding Exicure’s business into innovative medical device technologies designed to address important unmet needs among patients with Parkinson’s disease,” said Jung Soo Kim, Chief Executive Officer of Exicure. “With more than a decade of development behind X-CUE and the product ready for planned clinical evaluation, we believe this initiative presents a promising opportunity to advance a differentiated technology toward commercialization and create long-term value for our stockholders.”

About X-CUE
X-CUE is an augmented-reality smart-glasses technology designed to assist patients with Parkinson’s disease who experience freezing of gait.

Developed over more than a decade, X-CUE provides visual cues intended to support mobility during freezing-of-gait episodes.

The product has completed its development phase and is being prepared for clinical evaluation, with an anticipated clinical trial period of approximately six months. Potential commercialization remains subject to successful clinical evaluation and applicable regulatory approvals.

About Exicure, Inc.
Exicure, Inc. (Nasdaq: XCUR) is a biotechnology company focused on advancing innovative healthcare technologies and pursuing strategic growth opportunities.

The Company’s portfolio includes a clinical-stage program targeting stem cell mobilization for multiple myeloma, sickle cell disease, and cell and gene therapy applications.

Exicure is expanding its strategic focus to include medical device technologies designed to address unmet needs in Parkinson’s disease and other healthcare markets.

For more information, visit www.exicuretx.com.

Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding the Company’s proposed acquisition of an equity interest in NeuroQ Biologics Inc., the anticipated issuance of Exicure common shares, potential development funding of up to $500,000, the continued development and clinical evaluation of X-CUE technology, the anticipated six-month clinical evaluation period, potential regulatory approvals, and future commercialization opportunities.

Words such as “plans,” “expects,” “will,” “anticipates,” “continue,” “believes,” “may,” “intend,” “could,” and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain such terms.

Forward-looking statements are based on management’s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results may differ materially due to various factors, including the inability to finalize or complete the proposed acquisition, failure to satisfy applicable closing conditions or obtain required approvals, funding limitations, clinical trial delays or unfavorable results, regulatory uncertainties, and challenges associated with the development and commercialization of X-CUE technology.

For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 25, 2026, as updated by the Company’s subsequent filings with the SEC.

All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Contact Information
Exicure, Inc.
Investor Relations
Email: pr@exicuretx.com 

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/745faad3-b4c6-4142-903f-8bd8dc930f8e
https://www.globenewswire.com/NewsRoom/AttachmentNg/dd8090ad-20f1-4e98-a4b6-d8ea0268c5eb

THIS PRESS RELEASE MAY NOT BE DISSEMINATED, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE ITS DISTRIBUTION, PUBLICATION OR DISSEMINATION WOULD BE ILLEGAL

Information on the contemplated simplification

Paris, 20 November 2026

As part of the project announced in the press release dated 23 September 2026, the Board of Directors of Christian Dior approved the proposed conversion of the Company into a limited joint-stock partnership (société en commandite par actions) (the “Conversion”) and the terms of merger with respect to the merger of Agache into Christian Dior (the “Merger”), which were signed today by both parties.1 The Board of Directors of Christian Dior also appointed an independent expert pursuant to article 261-1, I, 1° of the AMF’s general regulation.

1. Details of the merger of Agache into Christian Dior

Under the terms of merger, Christian Dior would issue 17.4 new shares for each Agache share and would cancel the Christian Dior shares held by Agache, so that the shares not held by the Arnault family group, representing 2.44% of the share capital as of the date of this press release, would represent 1.91% of the share capital following these transactions. The listed company resulting from the Merger would then mainly hold a direct stake in LVMH of 49.76% of the share capital and 65.55% of the voting rights2.

A General Meeting of the shareholders of Christian Dior will be convened for 30 December 2026 to vote on the Merger and the Conversion. The related documents will be made available to the shareholders by 30 November, including the report of the Board of Directors, the draft terms of merger and the information document relating to the Merger filed with the AMF, which describes how the exchange ratio was determined. The shareholders will also have access to the reports of the merger auditors (commissaires à la fusion) on the value of the contributions and on the fairness of the exchange ratio.

Completion of the Merger is subject to conditions precedent such as obtaining waivers from the AMF with respect to any obligation to file mandatory tender offers on Christian Dior and LVMH that would result from the Merger, and is subject to the approval of the general meetings of the shareholders of Agache and of Christian Dior; the Arnault family group remaining free regarding its decision as to the Merger and the Conversion.

2. Tender offer by the Arnault family group for Christian Dior shares, without implementing a squeeze-out

It is reminded that the Conversion, if completed, would trigger the filing by the Arnault family group of a tender offer (offre publique de retrait) for the Christian Dior shares it does not hold, paid entirely in cash and not followed by a squeeze-out (the “Offer”).

As announced on 23 September 2026, the Arnault family group intends to propose in the draft Offer a price equal to 95% of the net asset value (actif net réévalué) of Christian Dior calculated on a look-through basis with reference to the one-month average of LVMH’s share price and the Company’s accounts as at 31 August 2026 which will be made available to the shareholders, adjusted for the interim dividends received from LVMH and which shall be paid by Christian Dior on 3 December 2026.

This Offer price3 would be determined on 23 December 2026 after market close, and the one-month volume-weighted average LVMH share price used for this purpose would be calculated over the period from 24 November to 23 December 2026 inclusive.4

The Board of Directors has set up an ad hoc committee composed of three directors: Mr. Tony Estanguet, Mr. Christian de Labriffe and Mr. Xavier Musca. On the recommendation of this committee and in accordance with applicable regulations, Finexsi, represented by Mr. Olivier Péronnet, has been appointed by the Board of Directors as independent expert with the task of issuing a fairness opinion on the financial terms of the Offer.

Following the General Meeting of 30 December 2026, the draft Offer would, as the case may be, be filed with the AMF in January 2027. After the filing of the Company’s draft response document, the draft Offer would be subject to a clearance decision by the AMF, following which the opening of the Offer would be expected to take place in the first quarter of 2027.

* * *

Contact: communication@dior-finance.com

IMPORTANT INFORMATION

This press release has been prepared for information purposes only. It does not constitute an offer to purchase or a solicitation to sell Christian Dior securities in any country, including France. It is not intended for distribution in any country other than France, except where such distribution is permitted by applicable laws and regulations.

In the event that the tender offer is filed, the documentation relating to the offer, including the terms and conditions of the offer, would be submitted to the AMF, which will assess its compliance with the applicable legal and regulatory provisions. The offer may only be opened once it has been declared compliant by the AMF.

The dissemination, publication or distribution of this press release, as well as the offer and its acceptance, may be subject to specific regulations or restrictions in certain countries. The offer will not be directed to persons subject to such restrictions, either directly or indirectly, and may not be accepted from any country where the offer would be subject to such restrictions. Accordingly, persons in possession of this press release are required to obtain information on, and comply with, any local restrictions that may apply. Christian Dior does not accept any liability for any breach of these restrictions by any person.

This document is a free translation into English of the original French document. It is not a binding document. In the event of a conflict in interpretation, reference should be made to the French version, which is the authentic text.


1 Following the completion today of the merger of Financière Agache into Agache; the French Financial Markets Authority (Autorité des marchés financiers – AMF) having already granted a waiver with respect to any obligation to file a mandatory tender offer on Christian Dior (AMF decision no. 226C1880 of 26 October 2026).

2   Bringing together substantially all of the Arnault family group’s stake in LVMH, which amounts to 50.33% of the share capital and 66.27% of the voting rights.

3 The Arnault family group has informed the Board of Directors that, should the methodology for determining the Offer price result in an Offer price below the volume-weighted average share price over the sixty trading days preceding the publication of the pre-offer notice, i.e., €411.63 cum dividend (which €6.05 per share amount will be paid on 3 December), it would request from the AMF an exemption from the price rule set out in article 233-3 of the AMF’s general regulation.

4 LVMH daily share prices up to and including 30 November, the day before the interim dividend ex-date, would be reduced by the amount of the €5.50 interim dividend paid on 3 December 2026.

Attachment

Pfizer’s $330 million upfront commitment to three pre-IND in vivo CAR-T programs highlights pharmaceutical industry interest in next-generation engineered T-cell platforms

SRX’s pending acquisition of CERo Therapeutics provides exposure to CER-1236, a clinical-stage engineered T-cell therapy with seven patients dosed in the ongoing Phase 1/1b CERTAIN-T trial

NORTH PALM BEACH, Fla., Nov. 20, 2026 (GLOBE NEWSWIRE) — SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today commented on recent industry activity in engineered T-cell therapies following the November 18, 2026 announcement by Pfizer Inc. (“Pfizer”) of an exclusive licensing agreement with Starna Therapeutics (“Starna”), and provided an update on its pending acquisition of CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo Holdings” and, together with CERo Therapeutics, “CERo”), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms.

According to Pfizer’s announcement, the agreement covers three pre-IND in vivo chimeric antigen receptor T-cell (“CAR-T”) programs focused on treating autoimmune diseases. Starna will receive an upfront payment of $330 million and is eligible to receive up to $2.3 billion in development and commercial milestone payments, as well as royalties on net sales of approved products. Pfizer also obtained rights to Starna’s technology in inflammation and immunology and in oncology. SRX and CERo are not parties to, and have no involvement in, the Pfizer–Starna agreement.

CERo’s approach differs in technology, therapeutic focus and stage of development. Its lead investigational product candidate, CER-1236, is being evaluated in patients with hematologic malignancies in the ongoing Phase 1/1b CERTAIN-T trial. CER-1236 is based on CERo’s proprietary Chimeric Engulfment Receptor T cell (“CER-T”) platform, which is designed to integrate characteristics of innate and adaptive immunity into a single therapeutic construct intended to engage multiple immune mechanisms against cancer.

“Pfizer’s agreement with Starna is a clear signal that large pharmaceutical companies continue to commit significant capital to differentiated engineered T-cell platforms, even before those programs reach the clinic,” said Kent Cunningham, Chief Executive Officer of SRX Global. “CERo’s technology and indications are different, and we do not view this transaction as a valuation benchmark for CERo. What it does reinforce is our conviction in the long-term strategic importance of this field. CER-1236 is already being evaluated in patients, and our focus remains on supporting the CERo team as it advances the CERTAIN-T trial and on working toward closing the proposed acquisition.”

On November 3, 2026, CERo announced that it had dosed the seventh patient in CERTAIN-T, the fourth patient in the trial’s second cohort. CERo reported no dose-limiting toxicities (“DLTs”) in the three previously treated second-cohort patients during the DLT assessment period, and has reported expansion of infused CER-1236 cells following administration. In its June 2026 update, CERo reported that the observed safety profile remained consistent with earlier findings of no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, DLTs or treatment-related severe adverse events during the DLT assessment window. CERo has also expanded its clinical trial sites, including the activation of the University of California, Davis, which also serves as the primary manufacturing site for CER-1236. These clinical results are preliminary, are based on a limited number of patients, and are not sufficient to establish the safety or efficacy of CER-1236.

On October 7, 2026, SRX announced that it had entered into a definitive purchase agreement under which CERo Therapeutics will become a wholly owned subsidiary of SRX Global.

About the CERTAIN-T Trial
The first-in-human, multicenter, open-label Phase 1/1b CERTAIN-T study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of CER-1236 in patients with hematologic malignancies. The study initially enrolled patients with acute myeloid leukemia (“AML”), including relapsed/refractory AML, measurable residual disease AML, and newly diagnosed TP53-mutated AML, and the protocol has since been amended to include transfusion-dependent myelodysplastic syndromes (“TD-MDS”), high-risk myelodysplastic syndromes (“HR-MDS”), and post-JAK inhibitor myelofibrosis (“MF”). Primary endpoints include safety and tolerability. Secondary endpoints include pharmacokinetics and measures of clinical response, including overall response rate (“ORR”), complete response (“CR”), composite complete response (“cCR”), and measurable residual disease (“MRD”).

About SRX Global Inc.
SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.

About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering is designed to integrate characteristics of innate and adaptive immunity into a single therapeutic construct intended to engage multiple immune mechanisms against cancer. CERo refers to these engineered cells as Chimeric Engulfment Receptor T cells (“CER-T”).

The Company’s lead investigational product candidate, CER-1236, is being evaluated in hematologic malignancies.

Forward-Looking Statements
This communication contains forward-looking statements within the meaning of applicable securities laws. These statements include, without limitation, statements regarding the proposed acquisition of CERo Therapeutics by SRX Global, including its expected timing and completion and the satisfaction of closing conditions; industry interest in and investment in engineered T-cell therapies; the clinical development, safety profile, pharmacokinetic and pharmacodynamic characteristics, therapeutic potential, and future evaluation of CER-1236; the progression, design, and enrollment of the CERTAIN-T trial; planned cohort expansion and dose escalation; and SRX Global’s and CERo’s development strategy and objectives. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Risks and uncertainties include, among others, the possibility that the proposed transaction is not completed on the anticipated timeline or at all; the failure to satisfy closing conditions; and the risks inherent in the clinical development of CER-1236, an investigational product candidate. Information in this communication regarding the Pfizer–Starna agreement is based solely on Pfizer’s public announcement, has not been independently verified by SRX, and should not be interpreted as indicating a valuation for CERo or SRX Global or the likelihood of any similar transaction. Information in this communication regarding CERo, CER-1236 and the CERTAIN-T trial is based on information provided or publicly disclosed by CERo. Prior to the closing of the proposed transaction, SRX does not control CERo and cannot guarantee CERo’s clinical, regulatory, or business outcomes.

Certain risks that could cause actual results to differ are set forth in SRX Global’s and CERo’s respective filings with the Securities and Exchange Commission, including their most recent Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in these filings are not exhaustive. Forward-looking statements are not guarantees of performance, and undue reliance should not be placed on such statements. SRX Global undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Company Contact
SRX Global Inc.
Kent Cunningham, Chief Executive Officer

Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
srx@kcsa.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.